Cowen Analysts Initiate Coverage on 3SBio Inc.

Date:2011-08-22hangmei  Text Size:
Related Company

Equities research analysts at Cowen initiated coverage on shares of 3SBio Inc. (SSRX.NSDQ) in a research note to investors on Friday. The analysts set an "outperform" rating on the stock.

Separately, analysts at JPMorgan Chase & Co. (NYSE: JPM) cut their price target on shares of 3SBio Inc. to $68.00 in a research note to investors on Wednesday, July 27th. Also, analysts at Zacks Investment Research reiterated a "neutral" rating on shares of 3SBio Inc. in a research note to investors on Thursday, May 12nd.

Shares of 3SBio Inc. opened at 13.87 on Monday. 3SBio Inc. has a 52 week low of $11.89 and a 52 week high of $20.00. The stock's 50-day moving average is $16.22 and its 200-day moving average is $16.58. The company has a market cap of $302.6 million and a price-to-earnings ratio of 25.31.

3SBio Inc. is a fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address large markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin, and an in-licensed product, Iron Sucrose Supplement. It is pursuing eight product candidates in late, mid and early-stage clinical and pre-clinical development, including a high dosage EPIAO, NuPIAO, a new indication for its TPIAO to treat idiopathic thrombocytopenic purpura (ITP), NuLeusin, a HPV vaccine for the prevention of cervical cancer, an anti-TNF monoclonal antibody product candidate, Feraheme (ferumoxytol) and Feraheme (ferumoxytol).

2005-2011 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1